GlassScriptPhysician profile
Francis C Te
NPI 1134158215
$11,691.30
in general payments reported to CMS, 2019-2025
56 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,837 · 2020: $1,424 · 2021: $1,332 · 2022: $1,984 · 2023: $2,375 · 2024: $2,400 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,114.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,112.26 | 2019-2025 | Creon, Linzess, Vraylar |
| Lilly USA, LLC | $841.15 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $771.99 | 2019-2024 | Prolia, Evenity, Krystexxa |
| Novartis Pharmaceuticals Corporation | $765.34 | 2019-2024 | |
| Pfizer INC. | $701.87 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $662.00 | 2021-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $611.06 | 2021-2025 | |
| Novo Nordisk INC | $407.75 | 2019-2024 | Rybelsus, Ozempic, Tresiba |
| Astrazeneca Pharmaceuticals LP | $396.77 | 2019-2024 | Farxiga, Fasenra, Lokelma |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $330.93 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $318.78 | 2019-2024 | Linzess |
| Sanofi-Aventis U.S. LLC | $313.04 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $214.39 | 2019-2023 | Xarelto |
| Radius Health, INC. | $181.19 | 2019-2020 | |
| Cvrx, INC. | $169.05 | 2024 | Barostim Neo System |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francis Te listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.